Abstract
Studies in animal models showed that antitumor immune response can be induced by a variety of cancer vaccines. This may also occur in the clinic, but the immune response in vaccinated cancer patients was rarely associated with a significant clinical response. This chapter will discuss (a) the crucial issue of the most appropriate tumor antigens (self vs. mutated) to be used for vaccination in human solid tumors; (b) the different factors that may impair antitumor immune response; (c) the reasons for the last, successful wave of vaccination trials; and (d) the role of combined vaccination and immunomodulation in the treatment of solid tumors.
Original language | English |
---|---|
Title of host publication | Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors |
Publisher | Springer Berlin Heidelberg |
Pages | 41-46 |
Number of pages | 6 |
ISBN (Print) | 9783662464106, 9783662464090 |
DOIs | |
Publication status | Published - Jan 1 2015 |
Keywords
- Progression
- Solid tumors
- Vaccination
ASJC Scopus subject areas
- Medicine(all)
- Immunology and Microbiology(all)